Truvestments Capital LLC Takes Position in VanEck Biotech ETF (NASDAQ:BBH)

Truvestments Capital LLC bought a new stake in VanEck Biotech ETF (NASDAQ:BBH) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 250 shares of the company’s stock, valued at approximately $44,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Truist Financial Corp lifted its position in VanEck Biotech ETF by 3.8% during the 2nd quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock worth $455,000 after buying an additional 100 shares in the last quarter. Mather Group LLC. acquired a new position in VanEck Biotech ETF during the 2nd quarter worth about $46,000. Red Lighthouse Investment Management LLC acquired a new position in VanEck Biotech ETF during the 2nd quarter worth about $51,000. Coastline Trust Co acquired a new position in VanEck Biotech ETF during the 3rd quarter worth about $59,000. Finally, Tyler Stone Wealth Management raised its holdings in VanEck Biotech ETF by 79.5% during the 3rd quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock worth $261,000 after purchasing an additional 652 shares during the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

Shares of NASDAQ:BBH opened at $167.03 on Thursday. VanEck Biotech ETF has a 1-year low of $148.52 and a 1-year high of $183.64. The business has a 50-day moving average price of $172.53 and a two-hundred day moving average price of $173.17.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.